source
- Replimune secures FDA accelerated approval for melanoma therapy after two prior rejectionsReplimune, a biotech based in Massachusetts, has received accelerated approval from the U.S. Food and Drug Administration for its melanoma drug. The approval comes after the therapy was rejected tw…
- FDA grants accelerated approval to Tudriqev viral therapy for PD-1-refractory advanced melanomaThe U.S. Food and Drug Administration has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically engineered oncolytic viral therapy for patients with advanced, tre…